Table 2 Patients exhibiting a positive response (increase in Treg of at least 30%), comparing baseline and treatment end (week 18) between rapamycin and placebo arm. Intention to Treat analysis

From: Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis

 

Positive response

Not positive response

Unadjusted analysis

Adjusted analysisa

n

%

n

%

RR

CI

p

OR

CI

P

Placebo

2

11.8

15

88.2

-

-

-

-

-

-

Rapamycin 1 mg/m2/d

5

27.8

13

72.2

2.36

0.42–13.12

0.2365

3.53

0.31–40.80

0.2477

Rapamycin 2 mg/m2/d

3

20.0

12

80.0

1.70

0.26–11.21

0.5220

2.76

0.20–37.58

0.3836

Rapamycin

8

25.0

25

75.8

2.06

0.49–8.65

0.2961

3.19

0.43–23.66

0.2567

  1. Source data are provided as a Source Data file.
  2. The unadjusted comparisons were carried out with a chi-square test without any correction and the adjusted comparisons with a logistic regression model. All statistical tests were two-tailed.
  3. RR relative risk, OR odds ratio, CI confidence interval.
  4. aAdjusted for sex, months from onset of symptoms, ALSFRS-R slope at baseline and treatment with edaravone.
Back to article page